



February 8, 2022

Rimba Glove SDN BHD  
% Michael Woude  
U.S Agent  
Emergo Global Representation LLC  
2500 Bee Cave Road  
Bldg 1, Suite 300  
Austin, Texas 78746

Re: K212898

Trade/Device Name: Blue Nitrile Powder Free Patient Examination Glove, Non-Sterile, Tested For Use  
With Chemotherapy Drugs

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-powdered patient examination glove

Regulatory Class: Class I, reserved

Product Code: LZA, LZC

Dear Michael Woude:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated **December 16, 2021**. Specifically, FDA is updating this SE Letter to address a typo in the sponsor name as an administrative correction.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Dr. Clarence Murray, OHT4: Office of Surgical and Infection Control Devices, 301-796-0870, [Clarence.Murray@fda.hhs.gov](mailto:Clarence.Murray@fda.hhs.gov).

Sincerely,

**Liqun Zhao-S**

For Clarence W. Murray, III, Ph.D  
Assistant Director  
DHT4B: Division of Infection Control  
and Plastic Surgery Devices  
OHT4: Office of Surgical  
and Infection Control Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health



December 16, 2021

Rimba Glove SND BHD  
% Michael Woude  
U.S Agent  
Emergo Global Representation LLC  
2500 Bee Cave Road  
Bldg 1, Suite 300  
Austin, Texas 78746

Re: K212898

Trade/Device Name: Blue Nitrile Powder Free Patient Examination Glove, Non-Sterile, Tested For Use  
With Chemotherapy Drugs

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I, reserved

Product Code: LZA, LZC

Dated: September 4, 2021

Received: September 10, 2021

Dear Michael Woude:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

  
**Liqun Zhao -S**

For Clarence W. Murray III, Ph.D.  
Assistant Director  
DHT4B: Division of Infection Control  
and Plastic Surgery Devices  
OHT4: Office of Surgical  
and Infection Control Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)  
K212898

Device Name

BLUE NITRILE POWDER FREE PATIENT EXAMINATION GLOVE, NON STERILE, TESTED FOR USE WITH CHEMOTHERAPY DRUGS

Indications for Use (Describe)

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs per ASTM D6978-05(2019) Standard Practice for assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

Chemotherapy Drug	Breakthrough Detection Time in Minutes
*Carmustine (BCNU)	23.0
Cisplatin	> 240
Cyclophosphamide (Cytosan)	> 240
Dacarbazine	> 240
Doxorubicin HCl	> 240
Etoposide	> 240
Fluorouracil	> 240
Ifosfamide	> 240
Methotrexate	> 240
Mitomycin C	> 240
Mitoxantrone	> 240
Paclitaxel	> 240
*Thiotepa	98.8
Vincristine Sulfate	> 240

\*CAUTION: Testing showed an average breakthrough time of 23.0 minutes for Carmustine and an average breakthrough time of 98.9 minutes for Thiotepa.

\*\*WARNING: DO NOT USE WITH CARMUSTINE.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

---

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
*PRAStaff@fda.hhs.gov*

*“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”*

# 510(k) SUMMARY - K212898

---

## 1.0 Submitter:

Name: Zahari Bin Darus  
Address: Rimba Glove Sdn Bhd  
Plot 37, Medan Tasek, Tasek Industrial Estate, 31400 Ipoh,  
Perak, Malaysia  
Phone No.: +605-5483688  
Fax No.: +605-5481688

Date of Summary Prepared: 20<sup>th</sup> August 2021 **(REVISED DATE: 7<sup>th</sup> Dec 2021)**

## 2.0 Identification of the subject device:

Trade Name : Blue Nitrile Powder Free Patient Examination Glove, Non-Sterile, Tested for use with Chemotherapy Drugs.  
Common Name : Patient Examination Gloves  
Classification Name : Patient Examination Gloves  
Device Classification : 1  
Regulation Number : 21 CFR 880.6250  
Product Code : LZA, LZC

## 3.0 Predicate Device:

### **K210944**

Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs (Blue).  
Company: Harbour Health LLC.

## 4.0 Description of The Device:

Blue Nitrile Powder Free Patient Examination Glove, Non-Sterile Tested for use with Chemotherapy Drugs meet all requirements of ASTM standard D6319 and FDA 21 CFR 880.6250.

The powder free nitrile examination glove is manufactured from nitrile rubber. Inner surface of gloves undergoes surface treatment process to produce a smooth surface that assists the user in donning the gloves with ease without using any lubricant such as powder on the glove surface. The glove is ambidextrous, i.e., can be worn on right hand or left hand.

## 5.0 Indication for use:

A patient examination glove is a disposable device made of nitrile rubber intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. The device has also been tested for use with Chemotherapy Drugs per ASTM D 6978-5(2019).

**WARNING: DO NOT USE WITH CARMUSTINE.**

## 6.0 Comparison of the Technological Characteristics of the Device:

The Blue Nitrile Powder Free Patient Examination Glove, Non-Sterile tested for use with chemotherapy drugs are summarized with the following technological characteristics compared to ASTM D6319 or equivalent standards as shown in Table 1.

## 510(k) SUMMARY - K212898

**Table 1**

CHARACTERISTICS	STANDARDS	DEVICE PERFORMANCE		COMPARISON ANALYSIS
		PREDICATE	CURRENT	
		BLUE	BLUE	
510(k) Number	-	K210944	K212898	
Manufacturer(s)	-	Harbour Health LLC, New Jersey 07059.	Rimba Glove Sdn Bhd	
Material	ASTM D6319	Nitrile	Nitrile	Same
Color	-	Blue	Blue	Same
Texture	-	Finger texture	Finger Texture	Same
Physical Properties	ASTM D6319			
<u>Before Aging</u> Tensile Strength: Ultimate Elongation:		≥ 14Mpa 500%	31.2Mpa 594%	Different but within the ASTM standard
<u>After Aging</u> Tensile Strength: Ultimate Elongation:		≥ 14Mpa 400%	34.7Mpa 553%	Different but within the ASTM standard
Thickness: - Finger - Palm	ASTM D6319	0.05mm 0.05mm	0.10mm 0.07mm	Different but within the ASTM standard
Powder Free	ASTM D6124	≤ 2 mg/glove	0.26 mg/glove	Different but within the ASTM standard

## 510(k) SUMMARY - K212898

CHARACTERISTICS	STANDARDS	DEVICE PERFORMANCE		COMPARISON ANALYSIS
		PREDICATE	CURRENT	
		BLUE	BLUE	
Biocompatibility	Primary Skin Irritation – ISO 10993-10:2010 (E) & Consumer Product Safety Commission Title 16, Chapter II, Part 1500	Under the condition of study, the device is a non-irritant	Under the conditions of study, the test material did not cause an irritant response. The Primary Irritant Response Category is deemed 'Negligible'	Similar
	Dermal Sensitization- ISO 10993-10: 2010 (E) & Consumer Product Safety Commission, Title 16, Chapter II, Part 1500.3 (c) (4)	Under the conditions of the study, the device is a non-sensitizer	Under the conditions of study, the test material did not produce a skin sensitization effect in the guinea pigs.	Similar
	Cytotoxicity - MEM Elution, ISO 10993-5: 2009 (E)	Under the conditions of the study, the device is potentially cytotoxic.	Under the conditions of study, the test material demonstrated a cytotoxic effect under the condition of this study. Additional test i.e. Acute Systemic Toxicity was tested.	Similar

## 510(k) SUMMARY - K212898

CHARACTERISTICS	STANDARDS	DEVICE PERFORMANCE		COMPARISON ANALYSIS
		PREDICATE	CURRENT	
		BLUE	BLUE	
Biocompatibility	Acute Systemic Toxicity, ISO 10993-11:2017 (E)	Under the conditions of study, the device does not elicit a systemic toxicity response in the model animal.	Under the conditions of study, the test item did not induce any systemic toxicity in Swiss albino mice.	Similar
Watertight (1000ml)	ASTM D 6319-19 ASTM D5151-19	Complies with ASTM D6319-19 and ASTM D5151-19, G-1, AQL 2.5	Gloves passed AQL 1.5	Different but well within the ASTM D6319-19
Intended use	-	The Harbour Health Powder Free Nitrile Examination Glove, Blue (Tested for use with Chemotherapy Drugs) is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. The proposed device was tested for use with Chemotherapy drugs per ASTM D6978-05(2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy drugs.	A patient examination glove is a disposable device made of nitrile rubber intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. The device has also been tested for use with Chemotherapy Drugs per ASTM D 6978-5(2019)	Same
Size	Medical Glove Guidance Manual – Labeling	Small Medium Large Extra Large	Extra Small Small Medium Large Extra Large	Similar
Single use	Medical Glove Guidance Manual – Labeling	Single Use	Single Use	Same

## 510(k) SUMMARY - K212898

CHARACTERISTICS	STANDARDS	DEVICE PERFORMANCE		COMPARISON ANALYSIS
		PREDICATE	CURRENT	
		BLUE	BLUE	
Chemotherapy Drugs Permeation Test		Minimum Breakthrough Detection Times in Minutes	Minimum Breakthrough Detection Times in Minutes	
Carmustine (BCNU) - 3.3 mg/ml	ASTM D6879-5(2019)	14.5	23.0	Different in the result
Cisplatin - 1.0 mg/ml		>240	>240	Same
Cyclophosphamide (Cytoxan) - 20.0 mg/ml		>240	>240	Same
Dacarbazine - 10.0 mg/ml		>240	>240	Same
Doxorubicin HCl - 2.0 mg/ml		>240	>240	Same
Etoposide - 20.0 mg/ml		>240	>240	Same
Fluorouracil - 50.0 mg/ml		>240	>240	Same
Ifosfamide - 50.0 mg/ml		>240	>240	Same
Methotrexate - 25 mg/ml		>240	>240	Same
Mitomycin C - 0.5 mg/ml		>240	>240	Same
Mitoxantrone - 2 mg/ml		>240	>240	Same
Paclitaxel - 6.0 mg/ml		>240	>240	Same
Thiotepa - 10 mg/ml		47.4	98.8	Different in the result
Vincristine Sulfate - 1 mg/ml		>240	>240	Same

## **510(k) SUMMARY - K212898**

---

There are no significant differences between the two products and they are the same or similar in terms of intended use, materials design, physical properties, thickness and biocompatibility test.

### **7.0 Summary of Non-Clinical Testing**

The performance test data of the non-clinical test for this powder free nitrile examination glove is summarized as per below.

## 510(k) SUMMARY - K212898

Test Method	Standard	Purpose of Testing	Acceptance Criteria			Results		Status
				Before aging	After aging	Before aging	After aging	
Physical Properties	ASTM D412 (Standard Test Method for Vulcanized Rubber and Thermoplastic Elastomers-Tension)	To evaluate the tensile (tension) properties of glove.	Tensile strength	Min 14.0 MPa	Min 14.0 MPa	31.2Mpa	34.7Mpa	Pass
			Ultimate elongation	Min 500%	Min 400%	594%	553%	Pass

## 510(k) SUMMARY - K212898

Test Method	Standard	Purpose of Testing	Glove Size	Acceptance Criteria		Results		Status
Dimension	ASTM D3767 Standard Practice for Rubber—Measurement of Dimensions	To measure the length, width and thickness of glove	X-Small	Length	Min 240 mm	Length	250 mm	Pass
				Width	70 ± 10 mm	Width	78.0 mm	Pass
				Thickness	Finger – min 0.05mm Palm – min 0.05mm	Thickness	0.10 mm 0.07 mm	Pass
			Small	Length	Min 240 mm	Length	250 mm	Pass
				Width	80 ± 10 mm	Width	88.0 mm	Pass
				Thickness	Finger – min 0.05mm Palm – min 0.05mm	Thickness	0.10 mm 0.07 mm	Pass
			Medium	Length	Min 240 mm	Length	250 mm	Pass
				Width	95 ± 10 mm	Width	98.0 mm	Pass
				Thickness	Finger – min 0.05mm Palm – min 0.05mm	Thickness	0.10 mm 0.07 mm	Pass
			Large	Length	Min 240 mm	Length	250 mm	Pass
				Width	110 ± 10 mm	Width	108 mm	Pass

## 510(k) SUMMARY - K212898

				Thickness	Finger – min 0.05mm Palm – min 0.05mm	Thickness	0.10 mm 0.07 mm	Pass
			X-Large	Length	Min 240 mm	Length	250 mm	Pass
				Width	120 ± 10 mm	Width	118 mm	Pass
				Thickness	Finger – min 0.05mm Palm – min 0.05mm	Thickness	0.10 mm 0.07 mm	Pass

## 510(k) SUMMARY - K212898

Test Method	Standard	Purpose of Testing	Acceptance Criteria	Results	Status
Watertight	ASTM D5151 (Standard Test Method for Detection of Holes in Medical Gloves)	To detect holes that leak water and thereby compromise the usefulness of the glove.	Sample size: <b>315</b> pcs Inspection level: G1 AQL: 1.5, Acceptance No. 10	The batch size for this sampling is 150,001 to 500,000. Hence, according to the single sampling plan GI, the sample to be drawn is under code M equivalent to 315 pieces with accept 10 and reject 11 to be accepted under AQL 1.5. During the test, 1 piece was found with leaks. Hence it falls within the acceptance criteria.	Pass

Test Method	Standard	Purpose of Testing	Acceptance Criteria	Results	Status
Residual Powder	ASTM D6124 (Standard Test Method for Residual Powder on Medical Gloves)	To determine the amount of residual powder and non-powder solids found on gloves.	Less than 2 mg per glove	Sample size : 5 pcs Requirement : <2mg/glove Result : 0.26mg/glove	Pass

## **510(k) SUMMARY - K212898**

---

### **8.0 Summary of Clinical Testing:**

No clinical study is included in this submission.

### **9.0 Conclusion**

The conclusion drawn from the non-clinical tests demonstrate that the subject Blue Nitrile Powder Free Patient Examination Glove, Non-Sterile is as safe, as effective, and performs as well as or better than the legally marketed predicate devices K210944.